D
Daniel W. Coyne
Researcher at Washington University in St. Louis
Publications - 145
Citations - 8098
Daniel W. Coyne is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Kidney disease & Anemia. The author has an hindex of 43, co-authored 141 publications receiving 7393 citations.
Papers
More filters
Journal ArticleDOI
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Geoffrey A. Block,Kevin J. Martin,Angel L.M. de Francisco,Stewart A. Turner,Morrell M. Avram,Michael Suranyi,Gavril Hercz,John Cunningham,Ali K. Abu-Alfa,Piergiorgio Messa,Daniel W. Coyne,Francesco Locatelli,Raphael M. Cohen,Pieter Evenepoel,Sharon M. Moe,Albert Fournier,Johann Braun,Laura C. McCary,Valter J. Zani,Kurt Olson,Tilman B. Drüeke,William G. Goodman +21 more
TL;DR: Cinacalcet lowers parathyroid hormone levels and improves calcium-phosphorus homeostasis in patients receiving hemodialysis who have uncontrolled secondary hyperparathyroidism.
Journal ArticleDOI
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
Dick de Zeeuw,Rajiv Agarwal,Michael Amdahl,Paul Audhya,Daniel W. Coyne,Tushar S. Garimella,Hans-Henrik Parving,Yili Pritchett,Giuseppe Remuzzi,Eberhard Ritz,Dennis L. Andress +10 more
TL;DR: Addition of 2 μg/day paricalcitol to RAAS inhibition safely lowers residual albuminuria in patients with diabetic nephropathy, and could be a novel approach to lower residual renal risk in diabetes.
Journal ArticleDOI
Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States.
Rajiv Agarwal,Allen R. Nissenson,Daniel Batlle,Daniel W. Coyne,J. Richard Trout,David G. Warnock +5 more
TL;DR: Control of hypertension, particularly systolic hypertension, in chronic hemodialysis patients in the United States is inadequate, despite recognition of its prevalence and the frequent use of antihypertensive drugs, and optimizing the use of medications and closer attention to nonpharmacologic interventions may improve control.
Journal ArticleDOI
Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study
Daniel W. Coyne,Toros Kapoian,Wadi N. Suki,Ajay K. Singh,John Moran,Naomi V. Dahl,Adel R. Rizkala +6 more
TL;DR: Administration of ferric gluconate 125 mg intravenously with eight consecutive hemodialysis sessions is superior to no iron therapy in anemic dialysis patients receiving adequate epoetin dosages and have a ferritin 500 to 1200 ng/ml and TSAT
Journal ArticleDOI
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Iain C. Macdougall,Andreas J. Bircher,Kai-Uwe Eckardt,Gregorio T. Obrador,Carol A. Pollock,Carol A. Pollock,Peter Stenvinkel,Dorine W. Swinkels,Christoph Wanner,Günter Weiss,Glenn M. Chertow,John W. Adamson,Tadao Akizawa,Stefan D. Anker,Michael Auerbach,Peter Bárány,Anatole Besarab,Sunil Bhandari,Ioav Cabantchik,Alan J. Collins,Daniel W. Coyne,Angel L.M. de Francisco,Steven Fishbane,Carlo A. J. M. Gaillard,Tomas Ganz,David Goldsmith,Chaim Hershko,Ewa A. Jankowska,Kirsten L. Johansen,Kamyar Kalantar-Zadeh,Philip A. Kalra,Bertram L. Kasiske,Francesco Locatelli,Jolanta Malyszko,Gert Mayer,Lawrence P. McMahon,Ashraf Mikhail,Elizabeta Nemeth,Amy Barton Pai,Patrick S. Parfrey,Roberto Pecoits-Filho,Simon D. Roger,Guy Rostoker,Jacques Rottembourg,Ajay K. Singh,Itzchak Slotki,Bruce Spinowitz,Der Cherng Tarng,Francesca Tentori,Jorge E. Toblli,Yusuke Tsukamoto,Nosratola D. Vaziri,Wolfgang C. Winkelmayer,David C. Wheeler,Elena Zakharova +54 more
TL;DR: An expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.